New drug trial targets scarring hair loss in women
NCT ID NCT06240351
Summary
This study is testing whether the drug baricitinib is safe and effective for treating frontal fibrosing alopecia (FFA), a condition that causes permanent hair loss and scarring. The trial will involve 15 adult women with active FFA who will take the medication to see if it reduces inflammation and disease activity. Researchers will measure changes in scalp symptoms, hairline recession, and eyebrow loss over the course of treatment.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes NO responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for FRONTAL FIBROSING ALOPECIA are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
University of Alabama at Birmingham
Birmingham, Alabama, 35233, United States
Conditions
Explore the condition pages connected to this study.